In 2020, a Brazilian study estimated that an investment of approximately €3250 in NGS testing is required to correctly identify a case of NSCLC with alterations in EGFR, ALK, or ROS1 (3 biomarkers) [48]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.